key: cord-0871144-8gxprkiu
authors: Ji, Dong; Qin, Enqiang; Lau, George
title: Reply to: ‘Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis’
date: 2020-05-11
journal: J Hepatol
DOI: 10.1016/j.jhep.2020.05.005
sha: 4548d153e65af030ae11908024cee731af573d48
doc_id: 871144
cord_uid: 8gxprkiu

nan

We declare no competing interests. illness in younger but not older patients. 1 As pointed out by the authors, a notable limitation of the study was the smaller sample size of the older cohort of patients, which might influence the validity of the results. Actually, if both aged groups were combined together and analyzed as a whole, MALFD subjects had a high likelihood of severe disease when compared with non-MAFLD subjects (26.9% vs 14.5% p =0.004). If multivariate analysis had been performed with the whole cohort, there was a high likelihood that MAFLD would be an independent factor for severe COVID-19, similarly to our observations. 2 On the other hand, in our previous study 3 which included 520 Chinese patients with biopsy-proven NAFLD/MAFLD, a statistically significant negative correlation between age and liver inflammation or fibrosis were found. This observation suggested that younger NAFLD/MAFLD patients might have more inflammation which in turn resulted in an increased risk of severe COVID-19 as shown in Zhou's study.

Therefore, in our opinion, both studies suggested that fatty liver disease is an independent risk factor for severe COVID-19 across all age groups. Further studies are warranted to understand the NAFLD/MAFLD role in the immunopathogenesis of COVID-19. 4 

Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study

The histological characteristics of patients with biopsy-proven non-alcoholic steatohepatitis

COVID-19: immunopathology and its implications for therapy